The cornea of the eye harbors a rich array of immune cells and nerve fibers, making it susceptible to characteristic changes induced by systemic autoimmune and vasculitic diseases, resulting in corneal manifestations like immune cell infiltration, alterations in nerve fibers leading to changes in corneal mucosal tissues, decreased tear secretion, modifications in meibomian gland structure and function manifesting as symptoms and signs of dry eye syndrome, posing challenges in treatment [310]
Methylglyoxal, the foe and friend of glyoxalase and Trx/TrxR systems in HT22 nerve cells
No regulatory body Health Canada, the FDA, the EMA, the TGA, or any equivalent has approved BPC-157 as a drug for human or veterinary use
Int J Mol Med (2015) 35(5):134754
Cell death was shown by the change in cell viability, which was calculated as: (viable cell)% = (optical density (OD) of untreated sample/OD of treated sample) 100